Jefferies disagrees 'on all accounts' with short seller report on AxoGen
AxoGen shares were down 25% yesterday following publication of a short report by Seligman Investments, noted Raj Denhoy. While a point-by-point refutation is not really feasible to a 114 page long report, he disagrees "on all accounts" with the short's claims that AxoGen's products are not differentiated, that the markets for its products are smaller and that the company is worth just a fraction of the stock's current valuation, Denhoy tells investors. Market size has always been a point of debate at AxoGen, but the analyst's work shows that its markets are "far more substantial" than the short seller claims. Additionally, no other company he is aware of is working on bringing a processed nerve allograft to the U.S. market, Denhoy said. He maintains a Buy rating and $45 price target on AxoGen shares.